艾塞那肽治疗并发代谢综合征的儿童Prader-Willi综合征1例体会

Abstract
Figure/Table
References (20)
Related Citation (4)

Download: PDF (354 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Prader-Willi syndrome is a genomic imprinting disease that is highly susceptible to childhood and adolescence obesity, multiplex syndromes of metabolic syndrome such as hypertension, hyperglycemia and dyslipidemia due to overfeeding and obesity will seriously affect the survival rate and quality of life of children. In this paper, a case of genetically diagnosed 9 years old Prader-Willi syndrome child complicated with metabolic syndrome is reported to analyse the data of blood pressure, body weight, biochemistry, liver imaging and sleep apnea monitoring before and after treatment of human glucagon like peptide -1 receptor agonist-exenatide, this child's appetite decreased and the satiety increased, body weight and body mass index decreased, blood pressure decreased and stable in the normal range, low density lipoprotein cholesterol decreased, high density lipoprotein cholesterol increased, the CT value of the liver increased, apnea hypoventilation index decreased and tolerance was good after 6 months of exenatide treatment. This study provides a new possibility for the treatment of such children.

Key words： Prader-Willi syndrome Metabolic syndrome Exenatide Nonalcoholic fatty liver disease Obstruction sleep apnea-hypopnea symdrome

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Haining YU Fei▲

Cite this article:

FANG Haining YU Fei▲. Treatment of exenatide of Prader-Willi syndrome complicated with metabolic syndrome：a case report[J]. 中国医药导报, 2018, 15(3): 159-162.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I3/159

[1] Bajrami E，Spiroski M. Genomic imprinting [J]. Open Access Maced J Med Sci，2016，4（1）：181-184.
[2] Boland CL，Harris JB，Harris KB. Pharmacological management of obesity in pediatric patients [J]. Ann Pharmacother，2015，49（2）：220-232.
[3] Bittel DC，Butler MG. Prader-Willi syndrome：clinical genetics，cytogenetics and molecular biology [J]. Expert Rev Mol Med，2005，7（14）：1-20.
[4] Brambilla P，Crinò A，Bedogni G，et al. Metabolic syndrome in children with Prader-Willi syndrome：the effect of obesity [J]. Nutr Metb Cardiovasc Dis，2011，21（4）：269-276.
[5] Hedgeman E，Ulrichsen SP，Carter S，et al. Long-term health outcomes in patients with Prader-Willi Syndrome：a nationwide cohort study in Denmark [J]. Int J Obes （Lond），2017，41（10）：1531-1538.
[6] Seufert J. Incretins and their endocrine and metabolic functions [J]. Endocr Dev，2017，32：38-48.
[7] ten Kulve JS，Veltman DJ，van Bloemendaal L，et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. [J]. Diabetologia，2015，58（12）：2688-2698.
[8] Nathan BM，Rudser KD，Abuzzahab MJ，et al. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity [J]. Clin Obes，2016，6（1）：73-78.
[9] Salehi P，Hsu I，Azen CG，et al. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome [J]. Pediatr Obes，2017， 12（3）：221-228.
[10] Purtell L，Sze L，Loughnan G，et al. In adults with Prader-Willi syndrome，elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels [J]. Neuropeptides，2011，45（4）：301-307.
[11] Ronveaux CC，Tomé D，Raybould HE，et al. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling [J]. J Nutr，2015，145（4）：672-680.
[12] Salehi P，Hsu I，Azen CG，et al. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome [J]. Pediatr Obes，2017， 12（3）：221-228.
[13] Kang YM，Jung CH. Cardiovascular effects of Glucagon-Like Peptide-1 receptor agonists [J]. Endocrinol Metab （Seoul），2016，31（2）：258-274.
[14] Kelly AS，Metzig AM，Rudser KD，et al. Exenatide as a weight-loss therapy in extreme pediatric obesity：a randomized，controlled pilot study [J]. Obesity （Silver Spring），2012，20：364-370.
[15] Okerson T，Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists [J]. Cardiovasc Ther，2012，30（3）：e146-e155.
[16] Tokuda M，Katsuno T，Ochi F，et al. Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes [J]. Endocr J，2014，61（4）：365-372.
[17] Shao N，Kuang HY，Hao M，et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes [J]. Diabetes Metab Res Rev，2014，30（6）：521-529.
[18] Liu J，Wang G，Jia Y， et al. GLP-1 receptor agonists：effects on the progression of non-alcoholic fatty liver disease [J]. Diabetes Metab Res Rev，2015，31（4）：329-335.
[19] 中华医学会儿科学分会内分泌遗传代谢学组，《中华儿科杂志》编辑委员会.中国Prader—Willi综合征诊治专家共识（2015）[J].中华儿科杂志，2015，53（6）：419-424.
[20] Blackman A，Foster GD，Zammit G，et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea：the SCALE Sleep Apnea randomized clinical trial [J]. Int J Obes（Lond），2016， 40（8）：1310-1319.